LUPIN - IntraDay Trade Analysis with Live Signals

Last Updated Time : 20 Dec 25, 07:03 am

IntraDay Trade Rating: 4.2

📊 Analysis: Lupin is trading at ₹2,124, comfortably above DMA 50 (₹2,035) and DMA 200 (₹1,992), confirming bullish undertone. RSI at 64 shows strength but not extreme overbought. MACD positive at 24.6 supports momentum continuation. Volume (5.29L) is slightly below 1-week average (6.28L), suggesting moderate intraday participation. Fundamentals remain strong with ROCE 21.9% and ROE 17.8%, though recent PAT decline is a cautionary factor.

💡 Optimal Buy Price: ₹2,115–₹2,125 (near support zone).

🎯 Profit-Taking Levels: ₹2,160 (first target), ₹2,185 (second target).

🛡️ Stop-Loss: ₹2,095 (below intraday support).

⏱️ If Already Holding: Exit near ₹2,160–₹2,185 if momentum slows or RSI nears 70. Cut position below ₹2,095 with rising volume to protect capital.

Positive

• 📈 Strong ROCE (21.9%) and ROE (17.8%)
• 💹 Low debt-to-equity (0.04) ensures balance sheet strength
• 📊 PEG ratio (0.11) highlights undervaluation relative to growth
• 📉 Price above DMA 50 & DMA 200, confirming bullish trend

Limitation

• 📉 PAT dropped from ₹2,128 Cr. to ₹869 Cr.
• 📊 Volume below average, limiting sharp intraday moves
• 📉 FII holding decreased (-0.75%), showing reduced foreign confidence

Company Negative News

• ⚠️ Profit decline impacting sentiment
• ⚠️ FII outflow may pressure stock short term

Company Positive News

• ✅ DII holding increased (+1.01%), showing domestic support
• ✅ Strong EPS (₹126) compared to peers
• ✅ Dividend yield (0.57%) adds investor confidence

Industry

• 🏥 Pharma sector PE at 30.6, Lupin at 18.2 — undervalued
• 📊 Defensive healthcare sector favored in volatile markets

Conclusion

🔎 Lupin is a solid intraday candidate with bullish technicals and undervaluation versus peers. Buy zone is ₹2,115–₹2,125 with targets at ₹2,160 and ₹2,185. Maintain stop-loss at ₹2,095. If already holding, exit near targets or on weakness below support with volume confirmation.

Would you like me to extend this into a peer benchmarking overlay with other pharma stocks or a sector rotation basket scan to strengthen intraday confirmation?